Torrent Pharma’s plant inspection (28 July–1 August 2025) ended with zero observations, affirming its strong compliance standards.

• Inspection concluded without any regulatory observations, reflecting Torrent’s quality control and manufacturing discipline.
• Torrent ranks 7th in India’s pharma market, excelling in chronic and sub-chronic therapeutic segments.
• 76% of domestic revenue comes from specialty-driven therapies like cardiovascular, CNS, and dermatology.